To Compare the Efficacy of Labetalol and Methyldopa in Treatment of Pregnancy Induced Hypertension
Dr. Neha Sharma, Dr. Alka Batar*

Assistant Professor, Department of Obstetrics and Gynaecology, SMS Medical College, Jaipur, Rajasthan, India

DOI: 10.36348/sijog.2020.v03i08.001 | Received: 20.07.2020 | Accepted: 27.07.2020 | Published: 06.08.2020
*Corresponding author: Dr. Alka Batar

Abstract

**Background:** The present study is undertaken with limited available facilities to find out the efficacy of two oral antihypertensive drugs namely labetalol and methyldopa in management of pregnancy induced hypertension. **Methods:** The study consisted of 150 patients with pregnancy induced hypertension attending outpatient department and admitted in ANW, or who directly came to labour room. These patients were randomly selected on lottery basis after they fulfilled the inclusion criteria. Total 150 patients were taken for the study and divided into 2 groups of 75 patients in each group. **Results:** The mean SBP before treatment in methyldopa group was 161.33 ± 8.97 mmHg and 160.03 ± 8.23 mmHg in labetalol group which showed a fall to 138.61 ± 6.67 mmHg (methyldopa group) and 138.08 ± 5.37 mmHg (labetalol groups) after treatment. Fall of MAP was significant in both the groups. But inter group difference was not significant (p > 0.05). The mean DBP before treatment was 106.85 ± 4.33 mmHg in methyldopa group and 105.63 ± 5.23 mmHg in labetalol group which decreased to 89.31 ± 6.51 mmHg and 89.68 ± 5.26 mmHg respectively after treatment. Fall of DBP was significant in both the groups. But inter group difference was not significant (p > 0.05). Fall of MAP was significant in Group A and Group B. But inter group difference was not significant (p > 0.05). **Conclusion:** Labetalol and methyldopa are equally efficacious in controlling blood pressure in new onset hypertension in pregnancy.

Keywords: Labetalol, Methyldopa, Hypertension.

INTRODUCTION

The modern obstetrical approach has been stepped up to keep the mother as well as the fetus away from the deleterious effects of maternal disease like hypertension till the pregnancy reaches its goal safely. But multifactorial behaviour of hypertension with individual variations makes the matter more complicated.

Early diagnosis, close medical supervision and timely delivery are the cardinal requirements of the management of the PIH. Antihypertensive drugs are often used to lower blood pressure with the aim of preventing this progression to adverse outcomes. There is now very strong evidence to support the use of anti hypertensive agents in all form of hypertension. Severe hypertension, conventionally defined as a BP of>160/110 mmHg, should be treated to prevent severe maternal complications [1-3].

Alpha Methyldopa is an α-methyl analogue of dopamine, the precursor of dopamine (DA) and noradrenaline. Methyldopa is the most frequently prescribed and the agent of first choice for treatment of hypertension in pregnancy. There is extensive clinical experience and long-term follow-up data regarding children whose mothers received methyldopa during pregnancy with proven maternal and fetal safety. Methyldopa is a weak antihypertensive drug that needs to be given three or four times a day and frequently requires titration and nonadherence to therapy [4].

Labetalol blocks both α- and β-adrenoceptors and produces its hypotensive effects without compromising the maternal cardiovascular system, and maintains renal and uterine blood flow. Little placental transfer occurs, mainly due to the negligible lipid solubility of the drug. Not only does labetalol satisfactorily control BP in pregnant women but may possibly aid the maturation of the fetal lung in utero [5].
MATERIAL AND METHODS

Study design
This study was hospital based comparative prospective study which included patients with pregnancy induced hypertension, attending the Antenatal Outpatient Department and admitted in Antenatal Ward or directly attending the labour room.

Study population
The study consisted of 150 patients with pregnancy induced hypertension attending outpatient department and admitted in ANW, or who directly came to labour room. These patients were randomly selected on lottery basis after they fulfilled the inclusion criteria. Total 150 patients were taken for the study and divided into 2 groups of 75 patients in each group.

The cases were selected and divided into two groups Group A and Group B. Each case with odd number was selected in the Group A and each case with even no. was selected in the Group B. Group a patients were treated with methyldopa and Group B patients treated with labetalol.

Selection of cases

Inclusion Criteria for study included the following:
- A singleton pregnancy.
- Patients who were booked before 20 weeks of gestation were taken up after they cross 20 weeks of gestation.
- Blood pressure exceeding 150 and 100 mm of Hg, systolic and diastolic respectively.

Exclusion Criteria included those with a

<table>
<thead>
<tr>
<th>AGE GROUP</th>
<th>GROUP A (n = 75)</th>
<th>GROUP B (n = 75)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;18</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>19—24</td>
<td>40</td>
<td>38</td>
</tr>
<tr>
<td>25—30</td>
<td>22</td>
<td>23</td>
</tr>
<tr>
<td>≥30</td>
<td>8</td>
<td>7</td>
</tr>
</tbody>
</table>

Maximum number of patients was between 19-24 years in both the groups. In Group a 40 (53.33%) patients and in Group B 38 (50.66%) patients were in this age group. The maximum age in the Group A was 34 years and 35 years in the Group B. The minimum age was 17 years in both the groups. The mean age in groups A was 24.4±4.55 years and in Group B 23.95±4.28 years. The inter group difference was not statistically significant (p>0.05) thus the two groups were comparable by age.

Method of data collection
An elaborate history was taken. General physical examination and systemic examinations were done.

For all the cases, dipstick test for urine albumin in random urine sample was done. Along with routine examination of pregnancy, liver function test, renal function test, coagulation profile was done. Ultrasonography was done in all the cases for estimation of gestational age, for placental localization, abruptio, to rule out congenital anomalies, multiple pregnancy etc.

If the patient was in labour, labour was monitored with partograph. The newborns were attended by pediatrician, examined and any complication noted was managed accordingly.

Blood pressure record was maintained after delivery till discharge. On discharge, discharge card was given and postoperative visits after 6 weeks, 12 weeks were advised.

RESULTS
Fall of DBP was significant in both the groups. But inter group difference was not significant (p > 0.05). Fall of MAP was significant in Group A and Group B. But inter group difference was not significant (p > 0.05). On comparing methyldopa and labetalol groups mean blood pressure before and after treatment was not statistically significant (p>0.05). Reduction in SBP, DBP, MAP was significant (p<0.05) in both the groups after treatment but intergroup difference in fall in blood pressure was not statistically significant (p>0.05).

The number of patient who required additional drugs to control the uncontrolled hypertension in Group a 2 (2.66%) patients and in Group B 3 (4%) patients did not respond with starting drug. These cases were started on an additional drug from the other groups and delivery was expedited. The inter group difference was not statistically significant (p>0.05).

**DISCUSSION**

150 patients with pregnancy induced hypertension, who attended the antenatal outpatient department and admitted or directly came to the labour room, had been studied. The patients were divided into 2 groups: Group patients were treated with methyldopa and Group B patients were treated with labetalol.

In the present study fall of SBP, DBP and MAP was significant in both the groups. But the inter group difference was statistically not significant (p>0.05). The mean SBP before treatment in methyldopa group was 161.33 ± 8.97 mmHg and 160.03 ± 8.23 mmHg in labetalol group which showed a fall to 138.61 ± 6.67 mmHg (methyldopa group) and 138.08 ± 5.37 mmHg (labetalol groups) after treatment. Fall of SBP was significant in both the groups. But inter group difference was not significant (p > 0.05). The mean DBP before treatment was 106.85 ± 4.33 mmHg in methyldopa group and 105.63 ± 5.23 mmHg in labetalol group which decreased to 89.31 ± 6.51 mmHg and 89.68 ± 5.26 mmHg respectively after treatment. Fall of DBP was significant in both the groups. But inter group difference was not significant (p > 0.05). Fall of MAP was significant in Group A and Group B. But inter group difference was not significant (p > 0.05). On comparing methyldopa and labetalol groups mean blood pressure before and after treatment was not statistically significant (p>0.05). Reduction in SBP, DBP, MAP was significant (p<0.05) in both the groups after treatment but intergroup difference in fall in blood pressure was not statistically significant (p>0.05).

<table>
<thead>
<tr>
<th>BLOOD PRESSURE</th>
<th>GROUP A</th>
<th>GROUP B</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Range</td>
<td>Mean BP ± SD (mmHg)</td>
<td>Range</td>
</tr>
<tr>
<td>SBP Before</td>
<td>150—184</td>
<td>161.33±8.97</td>
<td>150—182</td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;0.05</td>
<td></td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>After</td>
<td>130—152</td>
<td>138.61±6.67</td>
<td>130—152</td>
</tr>
<tr>
<td>DBP Before</td>
<td>100—120</td>
<td>106.85±4.33</td>
<td>100—120</td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;0.05</td>
<td></td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>After</td>
<td>80—104</td>
<td>89.31±6.51</td>
<td>80—104</td>
</tr>
<tr>
<td>MAP Before</td>
<td>116.66—140.66</td>
<td>125.01±4.39</td>
<td>116.66—140</td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;0.05</td>
<td></td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>After</td>
<td>116.66—140.66</td>
<td>105.74±5.16</td>
<td>96.66—120</td>
</tr>
</tbody>
</table>

The number of patient who required additional drugs used in group a and group B

<table>
<thead>
<tr>
<th>Uncontrolled hypertension</th>
<th>GROUP A (n = 75)</th>
<th>GROUP B (n = 75)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td>%</td>
<td>No.</td>
</tr>
<tr>
<td>Uncontrolled Hypertension</td>
<td>2</td>
<td>66</td>
</tr>
</tbody>
</table>

**Table-3: Number of patients who required additional drug used in group a and group B**

© 2020 | Published by Scholars Middle East Publishers, Dubai, United Arab Emirates

fall from 143.50±7.30mmHg/101.30±3.93 (sytolic/diastolic) on 1st day to 126.10±5.49 mmHg/87.40±5.62 mmHg (sytolic/diastolic) on day 7, while systolic/diastolic BP in methylodopa group on 1st day was 145.20±7.17 mmHg/101.60±4.20 mmHg which was reduced to 129.20±4.86 mmHg/90.50±3.30 mmHg on day 7. Author found that MAP in Labetalol group reduced from 115.226±4.17 mmHg to 100.17±4.43 mmHg on day 7 while in Methylene dopa group had MAP on admission 115.99±4.38 mmHg and on day 7 it reduced to 103.27±2.99 mmHg which is highly significant.

CONCLUSION

Labetalol and methylodopa are equally efficacious in controlling blood pressure in new onset hypertension in pregnancy. Labetalol significantly decreases proteinuria after treatment.

REFERENCES